Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy

Future Oncol. 2018 Oct;14(24):2493-2505. doi: 10.2217/fon-2018-0167. Epub 2018 Jul 3.

Abstract

Aim: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy.

Materials & methods: We studied the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio in 151 patients with mGC at the diagnosis.

Results: Median overall survival (OS) was significantly lower in patients with high NLR. Performance status 1-2 according to the Eastern Cooperative Oncology Group scale and NLR were predictors of shorter OS at multivariate analysis. Based on these results, we defined a prognostic OS score, showing a better median OS in favorable risk group.

Conclusion: Elevated pretreatment NLR and Eastern Cooperative Oncology Group are independent predictors of shorter OS in mGC patients before first-line chemotherapy.

Keywords: metastatic gastric cancer; neutrophil–lymphocyte ratio; platelet–lymphocyte ratio.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • Blood Platelets
  • Disease-Free Survival
  • Female
  • Humans
  • Inflammation / blood*
  • Kaplan-Meier Estimate
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Neutrophils
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / blood*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / immunology

Substances

  • Biomarkers, Tumor